CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
N-13 ammonia or F-18 fluorodeoxyglucose +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02018107
NCT02018107N/ACompleted

PET/CT-Guided Liver Tumor Ablation: Intraprocedural Assessment of Results Using Ammonia Perfusion PET

Dana-Farber Cancer Institute·interventional·Posted Dec 23, 2013·Updated Mar 26, 2020

In Brief

A clinical study evaluating N-13 ammonia or F-18 fluorodeoxyglucose and PET scan for Liver Tumor and Liver Neoplasms. Completed, enrolled 33 participants across 2 sites.

Detailed Summary

In this research study, the investigators are evaluating whether ammonia PET scans or FDG PET perfusion scans are more useful in helping radiologists determine whether liver tumors were successfully destroyed by the heating or freezing procedures (ablations) than other scans currently available to radiologists, such as CT scans and MRI scans. The currently available scan (usually a CT scan with contrast dye) is not always effective in showing how completely the tumor has been destroyed. The ammonia PET scan is a different way of looking at how much tumor has been destroyed. This study will compare the standard scan (CT scan) with the ammonia PET scan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 23, 2013
Enrollment StartJan 1, 2014
Primary CompletionFeb 16, 2018
Study CompletionFeb 16, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.5 years ago

Interventions

N-13 ammonia or F-18 fluorodeoxyglucoseother

PET tracer

PET scanother

PET scan